Sulfinpyrazone

Sulfinpyrazone is an oral uricosuric agent and pyrazolone derivative used primarily for the management of chronic gout (gouty arthritis). It works by competitively inhibiting the reabsorption of uric acid at the proximal convoluted tubule in the kidney, thereby increasing urinary excretion of uric acid and lowering plasma urate concentrations. This action is likely mediated through inhibition of transporters such as Urate anion transporter 1 (URAT1) and Organic anion transporter 4 (OAT4). Sulfinpyrazone does not possess anti-inflammatory or analgesic properties and is not effective for treating acute gout attacks. Additionally, it has platelet inhibitory effects by reducing platelet aggregation—likely through inhibition of degranulation and cyclo-oxygenase activity—which can reduce thrombotic risk in certain clinical settings. The drug has also been shown to inhibit UDP-glucuronosyltransferase and CYP2C9 enzymes[1][5][6][7][8].

Brand names

AnturanAnturaneApo-sulfinpyrazone

Other names

sulfinpyrazone